Crinetics Approach

Crinetics Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference

March 7, 2018 at 12:00 AM EST

SAN DIEGO – March 7, 2018 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers, Ph.D., founder and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 10:30 a.m. ET. The conference is being held from March 12-14, 2018 in Boston.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical-stage biotechnology company focusing on treatments for rare endocrine disorders and endocrine-related cancers. The company is currently conducting a Phase 1 trial with its oral nonpeptide somatostatin agonist, CRN00808, for the treatment of acromegaly, an orphan disease affecting more than 24,000 people in the United States. The company is also developing other oral nonpeptide somatostatin agonists for hyperinsulinism and neuroendocrine tumors, as well as an oral small molecule for Cushing’s disease. Crinetics was founded by a team of scientists with a proven track record of endocrine drug discovery and development. The company is backed by top life sciences investors and is headquartered in San Diego.